Kate Morling
katemorling.bsky.social
Kate Morling
@katemorling.bsky.social
Postdoctoral Research Fellow working on HIV in Towers Lab UCL 🦠
Excited to share the preprint for our work on cyclosporine-based lentiviral transduction enhancer, BG147, which degrades innate immune barrier IFITM3, increasing gene delivery in gene therapy.

Huge thanks to everyone involved! @towerslab.bsky.social

www.biorxiv.org/content/10.1...
A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3
Intrinsic innate immune barriers have evolved to suppress viral infection and can reduce effective gene delivery in gene therapy. We have developed BG147, a novel cyclosporine A analogue, optimised vi...
www.biorxiv.org
September 2, 2025 at 3:34 PM
Reposted by Kate Morling
Towers Lab attending @londoninfectionecr.bsky.social (LINE) annual symposium. Great talk lineups at the Francis Crick Institute, London. #LINE #ScienceIsCool.
June 9, 2025 at 12:42 PM
Reposted by Kate Morling
Virtual Virology is back - our first ever phage session. Do join us...
May 8, 2025 at 6:09 PM
Reposted by Kate Morling
First paper of 2025 is out now! 🎉

Our talented postdocs @katemorling.bsky.social and @melghazaly.bsky.social review latest advancements of how HIV capsid and accessory proteins Vpx/Vpr have evolved (or not) to regulate host innate immunity.

www.microbiologyresearch.org/content/jour...
January 14, 2025 at 3:30 PM